tissue array blocks bl2081 Search Results


90
TissueArray.com LLC four human bladder cancer tissue arrays (bl801, bl804, bl806 and bl208)
Four Human Bladder Cancer Tissue Arrays (Bl801, Bl804, Bl806 And Bl208), supplied by TissueArray.com LLC, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/tissue+array+blocks+bl2081/four+human+bladder+cancer+tissue+arrays++bl801++bl804++bl806+and+bl208+/pm24222607-44-1-14
Average 90 stars, based on 1 article reviews
four human bladder cancer tissue arrays (bl801, bl804, bl806 and bl208) - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
Biomax Inc human bladder cancer tissue microarray bl208
Human Bladder Cancer Tissue Microarray Bl208, supplied by Biomax Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/tissue+array+blocks+bl2081/human+bladder+cancer+tissue+microarray+bl208/pm33543020-212-12-11
Average 90 stars, based on 1 article reviews
human bladder cancer tissue microarray bl208 - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
ATCC cancer type source morphology atcc number designation
Cell lines used.
Cancer Type Source Morphology Atcc Number Designation, supplied by ATCC, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/tissue+array+blocks+bl2081/NCI-BL2087/pmc04586259-73-36-40
Average 90 stars, based on 1 article reviews
cancer type source morphology atcc number designation - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
TissueArray.com LLC pathological tissue array (#bl2081b)
Macrophages increase the resistance of bladder cancer to cisplatin. (A) The correlation between macrophage infiltration and OS in patients with bladder cancer was analyzed by the TIMER2.0 website. (B) The correlation between CD163 expression and OS in patients with bladder cancer was analyzed by the Kaplan–Meier‐plotter cancer database. The high versus low expression levels of CD163 mRNA were split by the upper tertile value. The threshold of follow‐up for patients was set at 60 months. (C) The expression of the CD163 gene in various <t>pathological</t> stages of bladder cancer was analyzed by the pathological stage plot on the GEPIA web server. The expression violin plots were generated using log 2 (TPM + 1) transformed expression data on the patient's pathological stage. (D) Cell viabilities of HT1376 and BFTC905 with or without 20% CM treatment in indicated doses of cisplatin for 24 h were determined by the MTT assay ( n = 3). The data were displayed as the means ± standard deviation (SD). P values were calculated using a two‐tailed unpaired Student's t ‐test (D). ** P < 0.01. CM, condition media; OS, overall survival; TPM, transcripts per million.
Pathological Tissue Array (#Bl2081b), supplied by TissueArray.com LLC, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/tissue+array+blocks+bl2081/bl2081/pmc11306518-132-16-22
Average 90 stars, based on 1 article reviews
pathological tissue array (#bl2081b) - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
U.S Biomax Inc bladder tumor tissue arrays bl2081
Macrophages increase the resistance of bladder cancer to cisplatin. (A) The correlation between macrophage infiltration and OS in patients with bladder cancer was analyzed by the TIMER2.0 website. (B) The correlation between CD163 expression and OS in patients with bladder cancer was analyzed by the Kaplan–Meier‐plotter cancer database. The high versus low expression levels of CD163 mRNA were split by the upper tertile value. The threshold of follow‐up for patients was set at 60 months. (C) The expression of the CD163 gene in various <t>pathological</t> stages of bladder cancer was analyzed by the pathological stage plot on the GEPIA web server. The expression violin plots were generated using log 2 (TPM + 1) transformed expression data on the patient's pathological stage. (D) Cell viabilities of HT1376 and BFTC905 with or without 20% CM treatment in indicated doses of cisplatin for 24 h were determined by the MTT assay ( n = 3). The data were displayed as the means ± standard deviation (SD). P values were calculated using a two‐tailed unpaired Student's t ‐test (D). ** P < 0.01. CM, condition media; OS, overall survival; TPM, transcripts per million.
Bladder Tumor Tissue Arrays Bl2081, supplied by U.S Biomax Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/tissue+array+blocks+bl2081/bladder+tumor+tissue+arrays+bl2081/pmc03108377-125-1-12
Average 90 stars, based on 1 article reviews
bladder tumor tissue arrays bl2081 - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
U.S Biomax Inc four human bladder cancer tissue arrays (bl801, bl804, bl806 and bl208)
Macrophages increase the resistance of bladder cancer to cisplatin. (A) The correlation between macrophage infiltration and OS in patients with bladder cancer was analyzed by the TIMER2.0 website. (B) The correlation between CD163 expression and OS in patients with bladder cancer was analyzed by the Kaplan–Meier‐plotter cancer database. The high versus low expression levels of CD163 mRNA were split by the upper tertile value. The threshold of follow‐up for patients was set at 60 months. (C) The expression of the CD163 gene in various <t>pathological</t> stages of bladder cancer was analyzed by the pathological stage plot on the GEPIA web server. The expression violin plots were generated using log 2 (TPM + 1) transformed expression data on the patient's pathological stage. (D) Cell viabilities of HT1376 and BFTC905 with or without 20% CM treatment in indicated doses of cisplatin for 24 h were determined by the MTT assay ( n = 3). The data were displayed as the means ± standard deviation (SD). P values were calculated using a two‐tailed unpaired Student's t ‐test (D). ** P < 0.01. CM, condition media; OS, overall survival; TPM, transcripts per million.
Four Human Bladder Cancer Tissue Arrays (Bl801, Bl804, Bl806 And Bl208), supplied by U.S Biomax Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/tissue+array+blocks+bl2081/Human+Prostate+Cancer/pmc04233981-18-1-14
Average 90 stars, based on 1 article reviews
four human bladder cancer tissue arrays (bl801, bl804, bl806 and bl208) - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
Biomax Inc tissue microarrays bl806
EGFR and HER2 expression in bladder cancer. ( A ) TCGA dataset was used to show increased expression of EGFR and HER2 in bladder cancer. (i) EGFR is significantly elevated in bladder cancer compared to normal urothelium ( P < 0.01; ANOVA), specifically in ‘basal’ subtype classes 3 and 4. (ii) HER2 is significantly elevated in bladder cancer compared to the normal urothelium ( P < 0.01; ANOVA), specifically in ‘luminal’ subtype classes 1 and 2. ( B ) Tissue microarrays <t>BL2081</t> and BL806 (Biomax) were analyzed for the presence of EGFR and HER2 expression. 232 BC samples were stained, and 186 (80%) samples showed presence of either EGFR, HER2, or both. Of those, 79 (42.4%) samples and 23 (12.4%) showed only EGFR expression and only HER2 expression, respectively. 84 (45.2%) samples showed co-expression of EGFR and HER2.
Tissue Microarrays Bl806, supplied by Biomax Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/tissue+array+blocks+bl2081/tissue+array+blocks+bl+806/pmc06375935-131-81-86
Average 90 stars, based on 1 article reviews
tissue microarrays bl806 - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
TissueArray.com LLC tissue microarrays (tma
EGFR and HER2 expression in bladder cancer. ( A ) TCGA dataset was used to show increased expression of EGFR and HER2 in bladder cancer. (i) EGFR is significantly elevated in bladder cancer compared to normal urothelium ( P < 0.01; ANOVA), specifically in ‘basal’ subtype classes 3 and 4. (ii) HER2 is significantly elevated in bladder cancer compared to the normal urothelium ( P < 0.01; ANOVA), specifically in ‘luminal’ subtype classes 1 and 2. ( B ) Tissue microarrays <t>BL2081</t> and BL806 (Biomax) were analyzed for the presence of EGFR and HER2 expression. 232 BC samples were stained, and 186 (80%) samples showed presence of either EGFR, HER2, or both. Of those, 79 (42.4%) samples and 23 (12.4%) showed only EGFR expression and only HER2 expression, respectively. 84 (45.2%) samples showed co-expression of EGFR and HER2.
Tissue Microarrays (Tma, supplied by TissueArray.com LLC, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/tissue+array+blocks+bl2081/tissue+microarrays/pm24885595-39-16-23
Average 90 stars, based on 1 article reviews
tissue microarrays (tma - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

95
ATCC 25302 lc2w p bd ii p p cect4040a atcc 25598a cect4043a atcc 11578a atcc 4545a bl101a bl106a bl193a bl208a bl227a
EGFR and HER2 expression in bladder cancer. ( A ) TCGA dataset was used to show increased expression of EGFR and HER2 in bladder cancer. (i) EGFR is significantly elevated in bladder cancer compared to normal urothelium ( P < 0.01; ANOVA), specifically in ‘basal’ subtype classes 3 and 4. (ii) HER2 is significantly elevated in bladder cancer compared to the normal urothelium ( P < 0.01; ANOVA), specifically in ‘luminal’ subtype classes 1 and 2. ( B ) Tissue microarrays <t>BL2081</t> and BL806 (Biomax) were analyzed for the presence of EGFR and HER2 expression. 232 BC samples were stained, and 186 (80%) samples showed presence of either EGFR, HER2, or both. Of those, 79 (42.4%) samples and 23 (12.4%) showed only EGFR expression and only HER2 expression, respectively. 84 (45.2%) samples showed co-expression of EGFR and HER2.
25302 Lc2w P Bd Ii P P Cect4040a Atcc 25598a Cect4043a Atcc 11578a Atcc 4545a Bl101a Bl106a Bl193a Bl208a Bl227a, supplied by ATCC, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/tissue+array+blocks+bl2081/Lactobacillus+paracasei+subsp%2E+paracasei+Collins+et+al/10__1128_slash_aem__02287___12-146-9-16
Average 95 stars, based on 1 article reviews
25302 lc2w p bd ii p p cect4040a atcc 25598a cect4043a atcc 11578a atcc 4545a bl101a bl106a bl193a bl208a bl227a - by Bioz Stars, 2026-11
95/100 stars
  Buy from Supplier

97
ATCC pseudomonas stutzeri jcm 5965
EGFR and HER2 expression in bladder cancer. ( A ) TCGA dataset was used to show increased expression of EGFR and HER2 in bladder cancer. (i) EGFR is significantly elevated in bladder cancer compared to normal urothelium ( P < 0.01; ANOVA), specifically in ‘basal’ subtype classes 3 and 4. (ii) HER2 is significantly elevated in bladder cancer compared to the normal urothelium ( P < 0.01; ANOVA), specifically in ‘luminal’ subtype classes 1 and 2. ( B ) Tissue microarrays <t>BL2081</t> and BL806 (Biomax) were analyzed for the presence of EGFR and HER2 expression. 232 BC samples were stained, and 186 (80%) samples showed presence of either EGFR, HER2, or both. Of those, 79 (42.4%) samples and 23 (12.4%) showed only EGFR expression and only HER2 expression, respectively. 84 (45.2%) samples showed co-expression of EGFR and HER2.
Pseudomonas Stutzeri Jcm 5965, supplied by ATCC, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/tissue+array+blocks+bl2081/Pseudomonas/pmc05478542__32_180_s1-38-81-94
Average 97 stars, based on 1 article reviews
pseudomonas stutzeri jcm 5965 - by Bioz Stars, 2026-11
97/100 stars
  Buy from Supplier

90
Orthofix Medical Inc external fixator orthofix m511
EGFR and HER2 expression in bladder cancer. ( A ) TCGA dataset was used to show increased expression of EGFR and HER2 in bladder cancer. (i) EGFR is significantly elevated in bladder cancer compared to normal urothelium ( P < 0.01; ANOVA), specifically in ‘basal’ subtype classes 3 and 4. (ii) HER2 is significantly elevated in bladder cancer compared to the normal urothelium ( P < 0.01; ANOVA), specifically in ‘luminal’ subtype classes 1 and 2. ( B ) Tissue microarrays <t>BL2081</t> and BL806 (Biomax) were analyzed for the presence of EGFR and HER2 expression. 232 BC samples were stained, and 186 (80%) samples showed presence of either EGFR, HER2, or both. Of those, 79 (42.4%) samples and 23 (12.4%) showed only EGFR expression and only HER2 expression, respectively. 84 (45.2%) samples showed co-expression of EGFR and HER2.
External Fixator Orthofix M511, supplied by Orthofix Medical Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/tissue+array+blocks+bl2081/external+fixator+orthofix+m511/pm25227332-64-3-6
Average 90 stars, based on 1 article reviews
external fixator orthofix m511 - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
Glaxo Smith bl2001/00003/00
EGFR and HER2 expression in bladder cancer. ( A ) TCGA dataset was used to show increased expression of EGFR and HER2 in bladder cancer. (i) EGFR is significantly elevated in bladder cancer compared to normal urothelium ( P < 0.01; ANOVA), specifically in ‘basal’ subtype classes 3 and 4. (ii) HER2 is significantly elevated in bladder cancer compared to the normal urothelium ( P < 0.01; ANOVA), specifically in ‘luminal’ subtype classes 1 and 2. ( B ) Tissue microarrays <t>BL2081</t> and BL806 (Biomax) were analyzed for the presence of EGFR and HER2 expression. 232 BC samples were stained, and 186 (80%) samples showed presence of either EGFR, HER2, or both. Of those, 79 (42.4%) samples and 23 (12.4%) showed only EGFR expression and only HER2 expression, respectively. 84 (45.2%) samples showed co-expression of EGFR and HER2.
Bl2001/00003/00, supplied by Glaxo Smith, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/tissue+array+blocks+bl2081/bl2001+00003+00/pm12959630-1113-0-1
Average 90 stars, based on 1 article reviews
bl2001/00003/00 - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

Image Search Results


Cell lines used.

Journal: Anticancer research

Article Title: Base Excision Repair Activities Differ in Human Lung Cancer Cells and Corresponding Normal Controls

doi:

Figure Lengend Snippet: Cell lines used.

Article Snippet: The cells were harvested at 80% confluence with trypsin, washed with PBS, and immediately processed for mitochondria and nuclei isolation. table ft1 table-wrap mode="anchored" t5 caption a7 Tumor cell lines Normal cell lines ATCC number (Designation) Cancer type Source Morphology ATCC number (Designation) Source Morphology NCI-H2087 ( CRL-5922 ) Adenocarcinoma; non-small cell lung cancer Lymphonode Epithelial NCI-BL2087 ( CRL-5965 ) Peripheral blood Lymphoblast NCI-H2107 ( CRL-5983 ) Carcinoma, small cell lung cancer Bone marrow Epithelial NCI-BL2107 ( CRL-5966 ) Peripheral blood Lymphoblast NCI-H2052 ( CRL-5915 ) Mesothelioma Pleural effusion – NCI-BL2052 ( CRL-5963 ) Peripheral blood Lymphoblast Open in a separate window Cell lines used.

Techniques:

Macrophages increase the resistance of bladder cancer to cisplatin. (A) The correlation between macrophage infiltration and OS in patients with bladder cancer was analyzed by the TIMER2.0 website. (B) The correlation between CD163 expression and OS in patients with bladder cancer was analyzed by the Kaplan–Meier‐plotter cancer database. The high versus low expression levels of CD163 mRNA were split by the upper tertile value. The threshold of follow‐up for patients was set at 60 months. (C) The expression of the CD163 gene in various pathological stages of bladder cancer was analyzed by the pathological stage plot on the GEPIA web server. The expression violin plots were generated using log 2 (TPM + 1) transformed expression data on the patient's pathological stage. (D) Cell viabilities of HT1376 and BFTC905 with or without 20% CM treatment in indicated doses of cisplatin for 24 h were determined by the MTT assay ( n = 3). The data were displayed as the means ± standard deviation (SD). P values were calculated using a two‐tailed unpaired Student's t ‐test (D). ** P < 0.01. CM, condition media; OS, overall survival; TPM, transcripts per million.

Journal: Molecular Oncology

Article Title: Glutathione S ‐transferase omega class 1 ( GSTO1 )‐associated large extracellular vesicles are involved in tumor‐associated macrophage‐mediated cisplatin resistance in bladder cancer

doi: 10.1002/1878-0261.13659

Figure Lengend Snippet: Macrophages increase the resistance of bladder cancer to cisplatin. (A) The correlation between macrophage infiltration and OS in patients with bladder cancer was analyzed by the TIMER2.0 website. (B) The correlation between CD163 expression and OS in patients with bladder cancer was analyzed by the Kaplan–Meier‐plotter cancer database. The high versus low expression levels of CD163 mRNA were split by the upper tertile value. The threshold of follow‐up for patients was set at 60 months. (C) The expression of the CD163 gene in various pathological stages of bladder cancer was analyzed by the pathological stage plot on the GEPIA web server. The expression violin plots were generated using log 2 (TPM + 1) transformed expression data on the patient's pathological stage. (D) Cell viabilities of HT1376 and BFTC905 with or without 20% CM treatment in indicated doses of cisplatin for 24 h were determined by the MTT assay ( n = 3). The data were displayed as the means ± standard deviation (SD). P values were calculated using a two‐tailed unpaired Student's t ‐test (D). ** P < 0.01. CM, condition media; OS, overall survival; TPM, transcripts per million.

Article Snippet: The expression of GSTO1 in human bladder normal tissues and tumor tissues was assessed using a pathological tissue array (#BL2081b) obtained from US Biomax in Derwood, MD, USA.

Techniques: Expressing, Generated, Transformation Assay, MTT Assay, Standard Deviation, Two Tailed Test

GSTO1 contributes to cisplatin resistance in bladder cancer. (A) The sample description of the pathological tissue array (Cat. No. BL2081b; US Biomax). (B) The expressions of GSTO1 in bladder normal ( n = 16) and cancer tissues ( n = 168) were analyzed using the pathological tissue array. Scale bar = 50 μm. (C) The H ‐score method was used to quantitatively assess the IHC results (normal = 16; cancer = 168). (D) The sample description of bladder cancer patients after cisplatin treatment. (E) The expressions of GSTO1 in high ( n = 5) and low ( n = 8) cisplatin response patients using IHC. Scale bar = 100 μm. (F) The GSTO1 positive area was used to quantitatively assess the IHC results (low response = 8; high response = 5). (G) Cell viabilities of cisplatin‐resistant HT1376 and BFTC905 and their controls at indicated doses of cisplatin for 24 h were determined by the MTT assay ( n = 3). (H) The expression of GSTO1 in cisplatin‐resistant HT1376 and BFTC905 and their controls was determined by western blot assay ( n = 3). β‐Actin, loading control. (I) Cell viability of GSTO1‐OE and the control HT1376 at the indicated doses of cisplatin for 24 h was determined by the MTT assay. GSTO1‐OE in HT1376 was validated by western blot assay (right panel) ( n = 3). (J) Cell viability of GSTO1‐KO and the control HT1376 at the indicated doses of cisplatin for 24 h was determined by the MTT assay. GSTO1‐KO in HT1376 was validated by Western blot assay (right panel) ( n = 3). (K) Cell viabilities of HT1376 with or without GSTO1 inhibitor GSTO1‐IN‐1 (1 μ m ) treatment in indicated doses of cisplatin for 24 h were determined by the MTT assay ( n = 3). The effect of GSTO1‐IN‐1 on GSTO1 expression of HT1376 was determined by Western blot assay (right panel) ( n = 3). (L) Cell viabilities of GSTO1‐KO and the control HT1376 in the presence or absence of CM (20%) in indicated doses of cisplatin for 24 h were determined by the MTT assay ( n = 3). (M) Cell viabilities of GSTO1‐KO and the control HT1376 in the presence or absence of TNF‐α (20 ng·mL −1 ) in indicated doses of cisplatin for 24 h were determined by the MTT assay ( n = 3). Data were displayed as the means ± SEM (C, F) or the mean ± SD (G, I–M). P values were calculated using a two‐tailed, unpaired Student's t ‐test (C, F, G, I–M). * P < 0.05; ** P < 0.01. cisplatin/R, cisplatin resistance; HGUC, high‐grade urothelial carcinoma; IHC, immunohistochemistry; KO, knockout; LGUC, low‐grade urothelial carcinoma; OE, overexpression.

Journal: Molecular Oncology

Article Title: Glutathione S ‐transferase omega class 1 ( GSTO1 )‐associated large extracellular vesicles are involved in tumor‐associated macrophage‐mediated cisplatin resistance in bladder cancer

doi: 10.1002/1878-0261.13659

Figure Lengend Snippet: GSTO1 contributes to cisplatin resistance in bladder cancer. (A) The sample description of the pathological tissue array (Cat. No. BL2081b; US Biomax). (B) The expressions of GSTO1 in bladder normal ( n = 16) and cancer tissues ( n = 168) were analyzed using the pathological tissue array. Scale bar = 50 μm. (C) The H ‐score method was used to quantitatively assess the IHC results (normal = 16; cancer = 168). (D) The sample description of bladder cancer patients after cisplatin treatment. (E) The expressions of GSTO1 in high ( n = 5) and low ( n = 8) cisplatin response patients using IHC. Scale bar = 100 μm. (F) The GSTO1 positive area was used to quantitatively assess the IHC results (low response = 8; high response = 5). (G) Cell viabilities of cisplatin‐resistant HT1376 and BFTC905 and their controls at indicated doses of cisplatin for 24 h were determined by the MTT assay ( n = 3). (H) The expression of GSTO1 in cisplatin‐resistant HT1376 and BFTC905 and their controls was determined by western blot assay ( n = 3). β‐Actin, loading control. (I) Cell viability of GSTO1‐OE and the control HT1376 at the indicated doses of cisplatin for 24 h was determined by the MTT assay. GSTO1‐OE in HT1376 was validated by western blot assay (right panel) ( n = 3). (J) Cell viability of GSTO1‐KO and the control HT1376 at the indicated doses of cisplatin for 24 h was determined by the MTT assay. GSTO1‐KO in HT1376 was validated by Western blot assay (right panel) ( n = 3). (K) Cell viabilities of HT1376 with or without GSTO1 inhibitor GSTO1‐IN‐1 (1 μ m ) treatment in indicated doses of cisplatin for 24 h were determined by the MTT assay ( n = 3). The effect of GSTO1‐IN‐1 on GSTO1 expression of HT1376 was determined by Western blot assay (right panel) ( n = 3). (L) Cell viabilities of GSTO1‐KO and the control HT1376 in the presence or absence of CM (20%) in indicated doses of cisplatin for 24 h were determined by the MTT assay ( n = 3). (M) Cell viabilities of GSTO1‐KO and the control HT1376 in the presence or absence of TNF‐α (20 ng·mL −1 ) in indicated doses of cisplatin for 24 h were determined by the MTT assay ( n = 3). Data were displayed as the means ± SEM (C, F) or the mean ± SD (G, I–M). P values were calculated using a two‐tailed, unpaired Student's t ‐test (C, F, G, I–M). * P < 0.05; ** P < 0.01. cisplatin/R, cisplatin resistance; HGUC, high‐grade urothelial carcinoma; IHC, immunohistochemistry; KO, knockout; LGUC, low‐grade urothelial carcinoma; OE, overexpression.

Article Snippet: The expression of GSTO1 in human bladder normal tissues and tumor tissues was assessed using a pathological tissue array (#BL2081b) obtained from US Biomax in Derwood, MD, USA.

Techniques: MTT Assay, Expressing, Western Blot, Control, Two Tailed Test, Immunohistochemistry, Knock-Out, Over Expression

EGFR and HER2 expression in bladder cancer. ( A ) TCGA dataset was used to show increased expression of EGFR and HER2 in bladder cancer. (i) EGFR is significantly elevated in bladder cancer compared to normal urothelium ( P < 0.01; ANOVA), specifically in ‘basal’ subtype classes 3 and 4. (ii) HER2 is significantly elevated in bladder cancer compared to the normal urothelium ( P < 0.01; ANOVA), specifically in ‘luminal’ subtype classes 1 and 2. ( B ) Tissue microarrays BL2081 and BL806 (Biomax) were analyzed for the presence of EGFR and HER2 expression. 232 BC samples were stained, and 186 (80%) samples showed presence of either EGFR, HER2, or both. Of those, 79 (42.4%) samples and 23 (12.4%) showed only EGFR expression and only HER2 expression, respectively. 84 (45.2%) samples showed co-expression of EGFR and HER2.

Journal: Scientific Reports

Article Title: Targeting Epidermal Growth Factor Receptor (EGFR) and Human Epidermal Growth Factor Receptor 2 (HER2) Expressing Bladder Cancer Using Combination Photoimmunotherapy (PIT)

doi: 10.1038/s41598-019-38575-x

Figure Lengend Snippet: EGFR and HER2 expression in bladder cancer. ( A ) TCGA dataset was used to show increased expression of EGFR and HER2 in bladder cancer. (i) EGFR is significantly elevated in bladder cancer compared to normal urothelium ( P < 0.01; ANOVA), specifically in ‘basal’ subtype classes 3 and 4. (ii) HER2 is significantly elevated in bladder cancer compared to the normal urothelium ( P < 0.01; ANOVA), specifically in ‘luminal’ subtype classes 1 and 2. ( B ) Tissue microarrays BL2081 and BL806 (Biomax) were analyzed for the presence of EGFR and HER2 expression. 232 BC samples were stained, and 186 (80%) samples showed presence of either EGFR, HER2, or both. Of those, 79 (42.4%) samples and 23 (12.4%) showed only EGFR expression and only HER2 expression, respectively. 84 (45.2%) samples showed co-expression of EGFR and HER2.

Article Snippet: Figure 1 EGFR and HER2 expression in bladder cancer. ( A ) TCGA dataset was used to show increased expression of EGFR and HER2 in bladder cancer. (i) EGFR is significantly elevated in bladder cancer compared to normal urothelium ( P < 0.01; ANOVA), specifically in ‘basal’ subtype classes 3 and 4. (ii) HER2 is significantly elevated in bladder cancer compared to the normal urothelium ( P < 0.01; ANOVA), specifically in ‘luminal’ subtype classes 1 and 2. ( B ) Tissue microarrays BL2081 and BL806 (Biomax) were analyzed for the presence of EGFR and HER2 expression.

Techniques: Expressing, Staining